GS
DFTX

GTS Securities’s Definium Therapeutics DFTX Stock Holding History

GTS Securities’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-23,900
Closed -$136K – 2982
2024
Q3 		$136K Buy
23,900
+8,400
+54% +$58.4K ﹤0.01% 3750
2024
Q2 		$112K Sell
15,500
-32,200
-68% -$282K ﹤0.01% 3593
2024
Q1 		$448K Sell
47,700
-25,733
-35% -$147K ﹤0.01% 2673
2023
Q4 		$269K Buy
73,433
+29,300
+66% +$88.2K ﹤0.01% 3303
2023
Q3 		$138K Buy
+44,133
New +$181K ﹤0.01% 3533

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GTS Securities's DFTX Position: Q4 2024 in Review

GTS Securities sold out of Definium Therapeutics (DFTX) in Q4 2024, closing a stake of 21,567 shares — an estimated $123K sold.

GTS Securities first reported a position in DFTX in Q3 2023 and held it in 4 quarters. The position peaked at $234K in Q1 2024. 172 funds tracked by Wall St. Rank hold DFTX as of Q4 2024.

  • GTS Securities reported no remaining Definium Therapeutics position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 21,567 Definium Therapeutics shares in Q4 2024, an estimated $123K.
  • GTS Securities first reported a position in Definium Therapeutics in Q3 2023 and held it in 4 quarters.
  • GTS Securities's Definium Therapeutics position peaked at $234K in Q1 2024.
  • 172 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.